These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 19606178)
1. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Seth A; Anderson DP; Albiani DA; Barton JJ Can J Ophthalmol; 2009 Aug; 44(4):467-8. PubMed ID: 19606178 [No Abstract] [Full Text] [Related]
2. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Phillips PM; Newman SA Arch Ophthalmol; 2008 Jan; 126(1):137-9. PubMed ID: 18195236 [No Abstract] [Full Text] [Related]
3. Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells--a report and review of 2 cases. Vora MM; Rodgers IR; Uretsky S Ophthalmic Plast Reconstr Surg; 2014; 30(4):e84-5. PubMed ID: 24814269 [TBL] [Abstract][Full Text] [Related]
4. Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation. Muruganandam M; Sandhu H J Clin Rheumatol; 2016 Oct; 22(7):384. PubMed ID: 27488454 [No Abstract] [Full Text] [Related]
5. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Missotten G; Verheezen Y Bull Soc Belge Ophtalmol; 2010; (315):23-4. PubMed ID: 21110506 [TBL] [Abstract][Full Text] [Related]
6. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Subramanian PS; Kerrison JB; Calvert PC; Miller NR Arch Ophthalmol; 2003 Sep; 121(9):1335-6. PubMed ID: 12963622 [No Abstract] [Full Text] [Related]
7. A Case Series and Review of Bisphosphonate-associated Orbital Inflammation. Lefebvre DR; Mandeville JT; Yonekawa Y; Arroyo JG; Torun N; Freitag SK Ocul Immunol Inflamm; 2016; 24(2):134-9. PubMed ID: 25153041 [TBL] [Abstract][Full Text] [Related]
8. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Ho JW; Sundar S Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101 [No Abstract] [Full Text] [Related]
9. Blind runner. Pelegrín L; Mesquida M; Rey A; Sánchez-Dalmau B; Frohman L Surv Ophthalmol; 2012 Sep; 57(5):486-94. PubMed ID: 22018675 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-associated orbital inflammation--a case report and review. Peterson JD; Bedrossian EH Orbit; 2012 Apr; 31(2):119-23. PubMed ID: 22489855 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy. Herrera I; Kam Y; Whittaker TJ; Champion M; Ajlan RS BMC Ophthalmol; 2019 Feb; 19(1):51. PubMed ID: 30764790 [TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Olson KB; Hellie CM; Pienta KJ Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106 [TBL] [Abstract][Full Text] [Related]
13. Potential effect of zoledronate therapy in heavy proteinuria. Gokden N; Zangari M; Elici F; Barlogie B; Kumar J Clin Nephrol; 2007 Apr; 67(4):263-5. PubMed ID: 17474565 [No Abstract] [Full Text] [Related]
14. Fever with rash following zolendronic acid administration. Rizos EC; Milionis HJ; Elisaf MS Clin Exp Rheumatol; 2006; 24(4):455. PubMed ID: 16956442 [No Abstract] [Full Text] [Related]
15. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Doggrell SA Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424 [TBL] [Abstract][Full Text] [Related]
16. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Gulley JL; Wu S; Arlen PM; Dahut WL Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715 [TBL] [Abstract][Full Text] [Related]